How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely PerformedVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement.